Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study

Roldão, Marisa; Escoli, Rachele; Gonçalves, Hernâni; Lobos, Ana Vila

doi:10.1007/s11255-022-03360-9

Cited by 3 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, intravenous formulations of high-titer iron are now available on the market, allowing large amounts of iron to be administered intravenously in a single dose. Ferric carboxymaltose and ferric derisomaltose, which can be administered intravenously in large doses at once resulting in a reduction in oxidative stress, has been reported to improve anemia, reduce ESA, and increase ferritin and TSAT [34][35][36][37][38][39][40]. However, it has been suggested that highdose iron administration and a high ferritin level are associated with iron deposition in the liver [41,42] and iron deposition in the liver and heart has also been reported to be observed in many hemodialysis patients [43].…”

Section: Discussionmentioning

confidence: 99%

High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy

Ogawa,

Tsuchiya,

Tomosugi

et al. 2024

IJMS

View full text Add to dashboard Cite

In vivo iron levels can be adjusted through intestinal iron absorption to be maintained at a suitable level; however, optimal iron levels in hemodialysis (HD) patients are unclear. In this study, we investigated total body iron (TBI), calculated as the sum of red blood cell (RBC) iron and iron stores, during courses of low-dose oral iron replacement therapy, and evaluated in vivo iron sufficiency and its indicators in HD patients. We analyzed data on 105 courses of low-dose iron replacement therapy administered to 83 patients on maintenance HD over 7 months. We evaluated changes in TBI, RBC iron, and iron stores from the initiation of treatment to month 7 in two groups of patients, namely, iron-therapy responders and non-responders. TBI showed significant increases until month 4 and plateaued thereafter in iron-therapy responders, and tended to increase and then reached a similar plateau in non-responders (month 7: 1900 ± 447 vs. 1900 ± 408 mg). Steady-state TBI was strongly correlated with body surface area (y = 1628.6x − 791.91, R2 = 0.88, p < 0.001). We observed constant TBI during oral iron replacement therapy suggesting the activation of a “mucosal block”. The results suggest that body surface area has utility for estimating the required TBI with regression equations.

show abstract

Section: Discussionmentioning

confidence: 99%

High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy

Ogawa,

Tsuchiya,

Tomosugi

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Neben der verminderten Bildung von Erythropoetin gibt es noch weitere Ursachen, die zur renalen Anämie beitragen. Dazu zählt auch ein Eisenmangel [3], bspw. als Folge einer verminderten Eisenaufnahme oder einer Unterernährung.…”

Section: Zusammenfassungunclassified

Verkürzte Lebensdauer der Erythrozyten als Determinante der renalen Anämie

Bissinger

2023

Nephrologie aktuell

View full text Add to dashboard Cite

ZUSAMMENFASSUNGIm Rahmen einer chronischen Nierenerkrankung (CKD: Chronic Kidney Disease) tritt häufig eine renale Anämie auf. Neben einer reduzierten Neubildung von Erythrozyten ist deren verkürzte Lebensdauer eine wichtige Determinante der renalen Anämie. Es konnte gezeigt werden, dass die Erythrozyten über den Mechanismus der Eryptose verfrüht aus der Blutbahn eliminiert werden, ohne dass es zu einer Hämolyse kommt. Dabei exprimieren die Erythrozyten den Marker Phosphatidylserin auf ihrer Oberfläche, was ein potentes Signal zur Phagozytose darstellt. Daraufhin werden die Erythrozyten rasch aus der Blutbahn entfernt. Die Ursache der stimulierten Eryptose bei CKD ist am ehesten auf eine komplexe Störung des inneren Milieus und des Erythrozytenstoffwechsels zurückzuführen.

show abstract

“…The patient's nephrologist determined all drug therapy. The indication of RBC transfusion was by the patient's nephrologists, which we recovered from the patient's medical chart history in whom ESA therapy was ineffective (e.g., erythropoietin resistance or patients with CKD and coronary heart disease with symptoms of anemia such as fatigue, reduced appetite, tiredness, and cognitive impairment) [11,12,23].…”

Section: Plos Onementioning

confidence: 99%

“…Management of CKD-related anemia consists of erythropoiesis-stimulating agents (ESA) and iron replacement [10][11][12]. Even so, the blood transfusion required to treat anemia in patients with CKD continues to be widely used, especially in patients with inflammation status who progress to kidney failure with replacement therapy requirements [13,14].…”

Section: Introductionmentioning

confidence: 99%

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Background Anemia is common in chronic kidney disease (CKD) and is associated with outcomes. In addition, serum soluble Fas (sFas) levels are related to anemia and erythropoietin (EPO) resistance. Objectives Firstly, to compare clinical data and serum levels of sFas, EPO, and pro-inflammatory markers between patients with non-dialytic CKD (NDD-CKD) and healthy subjects. Subsequently, to compare and evaluate the relationship of serum EPO, sFas levels with anemia, and outcomes in patients with NDD-CKD over a long follow-up period. Methods We performed a retrospective study in 58 NDD-CKD patients compared with 20 healthy subjects on complete blood count, kidney function, serum EPO, sFas, and inflammatory markers (CRP, IL- 6, and IFN-γ) at baseline. We then compared the same baseline data between patients with NDD-CKD who evolved to anemia and those who did not have anemia over the follow-up. We also evaluated the frequency of outcomes in patients with CKD with higher sFas levels. Finally, we performed a multivariate analysis of factors associated with CKD anemia. Results There were lower eGFR and Hb but higher serum inflammatory markers, sFas levels, sFas/eGFR, and EPO/Hb ratios in patients with NDD-CKD. Comparatively, on the other hand, NDD-CKD patients with anemia had lower eGFR but were older, had more diabetes, and had higher sFas/ eGFR, EPO/Hb ratios, and serum levels of IL-6 and sFas than NDD-CKD without anemia for an extended period. In addition, there was an association in a multivariate analysis of diabetes, age, and sFas levels with kidney anemia. Furthermore, there were higher frequencies of outcomes in increased serum sFas levels. Conclusion As an elective risk factor, serum sFas levels, in addition to age and diabetes, were independently associated with kidney anemia for an extended period. Thus, more studies are necessary to analyze the proper relationship of sFas with kidney anemia and its outcomes and therapy in CKD.

show abstract

Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study

Cited by 3 publications

References 18 publications

High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy

High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy

Verkürzte Lebensdauer der Erythrozyten als Determinante der renalen Anämie

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

Contact Info

Product

Resources

About